Sign in
BCAB Stock Price, Chart, Stats & News
BioAtla, Inc.
Save
4.92M
Market cap
–
Current P/E
–
Forward P/E
BCAB chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -406.76% |
ROE | 780.31% |
D/E | -0.20x |
Interest coverage ratio | – |
BCAB valuation
P/E | – |
P/S | – |
P/B | -0.29x |
P/CF | -0.16x |
P/FCF | -0.21x |
P/OCF | -0.16x |
PEG | 0.03x |
EV multiple | -0.16x |
About
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer.
Similar securities
Based on sector and market capitalization
Report issue